Windward Bio prices $175 million Nasdaq IPO

By Public Technologies
  • Windward Bio priced a $175 million Nasdaq IPO, excluding the greenshoe option.
  • A concurrent $50 million private placement with Sanofi brings expected gross proceeds from both transactions to $225 million.
  • Novo Holdings invested in Windward in January 2025.
  • In September 2026, Windward reported positive interim asthma results for WIN378 and initiated Phase 3.
  • Windward develops ultra-long-acting antibodies for respiratory and dermatological diseases; lead candidate WIN378 is designed for twice-yearly dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.